BACKGROUND: The standard therapy for brain metastasis (BM) in non-small cell lung cancer (NSCLC) is radiation therapy (RT), although it is associated with complications such as leukoencephalopathy. In the current report, we retrospectively review data from eight patients who had NSCLC and harbored epidermal growth factor receptor (EGFR) mutations, and who were received erlotinib plus bevacizumab (E+B) as first-line therapy for BM. METHODS: Patients were given E+B as first therapy for BM until August 2017 at our institution. Patients receiving local therapy for BM, such as surgery or radiotherapy, were excluded. Patients were administered erlotinib orally (once daily at 150 mg/body) plus bevacizumab by intravenous infusion (15 mg/kg on day 1 of a 21- or 28-day cycle). RESULTS: Eight NSCLC patients who were diagnosed with BM received E+B, including 2 men and 6 women with a median age of 65 years (range, 46-84 years). Four patients had an L858R EGFR mutation, while the other four had an exon 19 deletion. Seven patients had a partial response to E+B treatment, and one had a complete response. The 2-year survival rate was 62.5%. Three patients who were pre-treated with gefitinib had an E+B treatment duration of less than 1 year. At the time of this analysis, four patients had BM-related neurologic symptoms and multiple BMs, and were still receiving E+B with no evidence of treatment failure after more than 1 year. CONCLUSIONS: E+B can be used as first-line therapy for BM, even in patients with BM-related neurologic symptoms and multiple BMs.
BACKGROUND: The standard therapy for brain metastasis (BM) in non-small cell lung cancer (NSCLC) is radiation therapy (RT), although it is associated with complications such as leukoencephalopathy. In the current report, we retrospectively review data from eight patients who had NSCLC and harbored epidermal growth factor receptor (EGFR) mutations, and who were received erlotinib plus bevacizumab (E+B) as first-line therapy for BM. METHODS: Patients were given E+B as first therapy for BM until August 2017 at our institution. Patients receiving local therapy for BM, such as surgery or radiotherapy, were excluded. Patients were administered erlotinib orally (once daily at 150 mg/body) plus bevacizumab by intravenous infusion (15 mg/kg on day 1 of a 21- or 28-day cycle). RESULTS: Eight NSCLC patients who were diagnosed with BM received E+B, including 2 men and 6 women with a median age of 65 years (range, 46-84 years). Four patients had an L858R EGFR mutation, while the other four had an exon 19 deletion. Seven patients had a partial response to E+B treatment, and one had a complete response. The 2-year survival rate was 62.5%. Three patients who were pre-treated with gefitinib had an E+B treatment duration of less than 1 year. At the time of this analysis, four patients had BM-related neurologic symptoms and multiple BMs, and were still receiving E+B with no evidence of treatment failure after more than 1 year. CONCLUSIONS: E+B can be used as first-line therapy for BM, even in patients with BM-related neurologic symptoms and multiple BMs.
Authors: T Iuchi; M Shingyoji; T Sakaida; K Hatano; O Nagano; M Itakura; H Kageyama; S Yokoi; Y Hasegawa; K Kawasaki; T Iizasa Journal: Lung Cancer Date: 2013-08-28 Impact factor: 5.705
Authors: Harvey J Mamon; Beow Yong Yeap; Pasi A Jänne; Jason Reblando; Sarah Shrager; Michael T Jaklitsch; Steven Mentzer; Jeanne M Lukanich; David J Sugarbaker; Elizabeth H Baldini; Stuart Berman; Arthur Skarin; Raphael Bueno Journal: J Clin Oncol Date: 2005-03-01 Impact factor: 44.544
Authors: C Schettino; M A Bareschino; A Rossi; P Maione; P C Sacco; G Colantuoni; E Rossi; C Gridelli Journal: Curr Cancer Drug Targets Date: 2012-03 Impact factor: 3.428
Authors: Myung-Ju Ahn; Dong-Wan Kim; Byoung Chul Cho; Sang-We Kim; Jong Seok Lee; Jin-Seok Ahn; Tae Min Kim; Chia-Chi Lin; Hye Ryun Kim; Thomas John; Steven Kao; Jonathan W Goldman; Wu-Chou Su; Ronald Natale; Sarit Rabbie; Bryony Harrop; Philip Overend; Zhenfan Yang; James Chih-Hsin Yang Journal: Lancet Respir Med Date: 2017-10-19 Impact factor: 30.700
Authors: Ida Cedrych; Maksymilian A Kruczała; Tomasz Walasek; Jerzy Jakubowicz; Paweł Blecharz; Marian Reinfuss Journal: Contemp Oncol (Pozn) Date: 2016-12-20